WHO consolidated guidelines on tuberculosis

1 Module 2: ScreeningSystematic screening for tuberculosis diseaseWHO consolidated guidelines ontuberculosisWHO consolidated guidelineson tuberculosis Module 2: screening Systematic screening for tuberculosis disease Systematic screening for tuberculosis diseaseModule 2: ScreeningWHO consolidated guidelines ontuberculosisSystematic screening for tuberculosis diseaseModule 2: ScreeningWHO consolidated guidelines ontuberculosisWHO consolidated guidelines on tuberculosis . Module 2: screening systematic screening for tuberculosis diseaseISBN 978 92 4-002267 6 (electronic version) ISBN 978 92 4-002268 3 (print version) World Health Organization 2021 Some rights reserved.

2 This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike IGO licence (CC BY-NC-SA IGO; ). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.

3 If you create a translation of this work, you should add the following disclaimer along with the suggested citation: This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition . Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization ( ).Suggested citation. WHO consolidated guidelines on tuberculosis .

4 Module 2: screening systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA (CIP) data. CIP data are available at , rights and licensing. To purchase WHO publications, see To submit requests for commercial use and queries on rights and licensing, see Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.

5 The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

6 The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.

7 In no event shall WHO be liable for damages arising from its use. Design and layout by Inis CommunicationiiiContentsAcknowledgements vAbbreviations and acronyms viiiDefinitions ixExecutive summary 11. Introduction Background Definition and objectives of systematic screening for TB disease Scope of the 2021 update Rationale for the guideline update Objectives of the guideline update Target audience 92. Recommendations for systematic screening for TB disease in targeted populations Systematic screening for TB disease in the general population Systematic screening for TB disease among people with structural risk factors for TB Systematic screening for TB disease among people living with HIV Systematic screening for TB disease among household and other close contacts of individuals with TB disease Systematic screening for TB disease in prisons and other penitentiary institutions Systematic screening for TB

8 Disease among miners and others exposed to silica dust Systematic screening for TB disease among people attending health care services who have clinical risk factors for TB 193. Recommendations for tools for systematic screening for TB disease Tools for screening for TB disease among the general population and high-risk groups Use of computer-aided detection software for automated reading of digital chest radiographs Tools for screening for TB disease among people living with HIV Tools for systematic screening for TB disease among children and adolescents 354.

9 Monitoring and evaluation Indicators Routines for recording and reporting Programmatic evaluations Initial calibration for computer-aided detection technologies 395. Research gaps screening for TB in targeted populations Tools for screening for TB Operational research 436. References 45 Supplementary Table 51 Web annexesWeb Annex A. Methods and Expert Annex B. GRADE Summary of Findings Annex C. GRADE Evidence to Decision production of the WHO consolidated guidelines on tuberculosis . Module 2: screening was coordinated and written by Cecily Miller, with support from Annabel Baddeley, Dennis Falzon and Matteo Zignol, under the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global tuberculosis Programme.

10 The WHO Global tuberculosis Programme gratefully acknowledges the contribution of all experts involved in producing these guidelines1. This update was funded by grants provided to WHO by the United States Agency for International Development and the Russian Development GroupThe Guideline Development Group (GDG) was composed of Denise Arakaki-Sanchez (Ministry of Health, Brazil), Omolola Atalabi (University College Hospital, Ibadan, Nigeria), Helen Ayles (London School of Hygiene and Tropical Medicine, United Kingdom of Great Britain and Northern Ireland, and Zambart, Zambia), David Branigan (Treatment Action Group, United States of America)